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Peter Fayers, PhD2,7 and Pål Klepstad, MD, PhD8,9
OBJECTIVES: To examine whether the inter-individual variation in constipation among patients receiving opioids for cancer pain is
associated with genetic or non-genetic factors.
METHODS: Cancer patients receiving opioids were included from 17 centers in 11 European countries. Intensity of constipation
was reported by 1,568 patients on a four-point categorical scale. Non-genetic factors were included as covariates in stratified
regression analyses on the association between constipation and 75 single-nucleotide polymorphisms (SNPs) within 15 candidate
genes related to opioid- or constipation-signaling pathways (HTR3E, HTR4, HTR2A, TPH1, ADRA2A, CHRM3, TACR1, CCKAR, KIT,
ARRB2, GHRL, ABCB1, COMT, OPRM1, and OPRD1).
RESULTS: The non-genetic factors significantly associated with constipation were type of laxative, mobility and place of care
among patients receiving laxatives (N= 806), in addition to Karnofsky performance status and presence of metastases among
patients not receiving laxatives (N= 762) (Po0.01). Age, gender, body mass index, cancer diagnosis, time on opioids, opioid dose,
and type of opioid did not contribute to the inter-individual differences in constipation. Five SNPs, rs1800532 in TPH1, rs1799971 in
OPRM1, rs4437575 in ABCB1, rs10802789 in CHRM3, and rs2020917 in COMT were associated with constipation (Po0.01). Only
rs2020917 in COMT passed the Benjamini–Hochberg criterion for a 10% false discovery rate.
CONCLUSIONS: Type of laxative, mobility, hospitalization, Karnofsky performance status, presence of metastases, and five SNPs
within TPH1, OPRM1, ABCB1, CHRM3, and COMT may contribute to the variability in constipation among cancer patients treated
with opioids. Knowledge of these factors may help to develop new therapies and to identify patients needing a more individualized
approach to treatment.
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INTRODUCTION
The inter-individual variation in analgesic response to opioids is
well known. There is also a large inter-individual variability in
constipation among both healthy volunteers1 and cancer
patients receiving opioids.2 Constipation is a significant symp-
tom among cancer patients receiving opioids, with prevalence
rates ranging from50 to100%andwith a potential to significantly
impair the quality of life.3–5 There is substantial evidence
suggesting that treatment of constipation in this population can
and should be improved. Still, constipation remains poorly
recognized and undertreated.6 Although laxatives are com-
monly prescribed, there is a surprising lack of evidence to guide
the choice of treatment for the individual patient.7
Constipation results from a lack of coordination between
motility, mucosal transport, and defecation reflexes.3,8 In
normal bowel function, these mechanisms are finely adjusted
via the enteric nervous system and a variety of gastrointestinal
hormones constituting an intricate interplay between agonists,
antagonists and receptors.3,8 Based on available information
about function, physiology, and bowel dysfunction, genetic
variants within genes encoding serotonin receptors and
associated proteins (HTR3E,9–12 HTR4,13 HTR2A,14,15 and
TPH116), α2 adrenergic receptors (ADRA2A
14,17), cholinergic
receptors (CHRM318), substance P receptor (TACR114,19,20),
cholecystokinin receptors (CCKAR18,21–23), the ghrelin-
obestatin preproprotein (GHRL24), and the proto-oncogene
c-kit (KIT 25,26) are candidates to influence the presence and
intensity of constipation in cancer patients.
Administration of opioids influences the enteric nervous
system signaling, delays gastric emptying and intestinal
transit, reduce gastrointestinal motility by suppressing the
excitability and neurotransmitter release from enteric muscu-
lomotor neurones, and inhibit secretion, leading to opioid-
induced constipation.18 The interplay between opioids and
bowel physiology is complex, but it has been shown that
opioids and α2-adrenoceptor agonists have similar effects in
the rat small intestine,17 that opioid agonists affect intestinal
motility by modulating cholinergic transmission,18 inhibit
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release of substance P and block the presynaptic CCK-
activated acetylcholine release.18,19 Tryptophan hydroxylase
1 (TPH1) is known to increase in chronic constipation.16
Chronic morphine administration increase c-Kit expression in
bowel fragments of rats.26 Selective 5-HT4 receptor ago-
nists,13 5-HT2 receptor blockers and grehlin have been shown
to improve opioid-induced constipation.15,24 These observa-
tions in studies related to opioids and bowel function
emphasize the potential influence of the candidate genes
identified from factors involved in bowel function in general.
In addition to the genetic variants related to constipation
mechanisms, genetic variants affecting the pharmacokinetic
and pharmacodynamic properties of opioids may also lead to
inter-individual variations in opioid response.27 Genetic varia-
tions within genes encoding proteins involved in absorption,
transport (ABCB1, adenosine triphosphate-binding cassette,
subfamily B, member 128–31), metabolism (COMT, catechol-
O-methyl transferase32,33), elimination, receptor binding, and
downstream signaling (OPRM1/K1/D1 opioid receptors3,34
and ARRB2, β-arrestin34–37) may contribute to the inter-
individual variations in constipation during opioid treatment.3,27
There is a lack of knowledge about the causes of inter-
individual differences in constipation during opioid treatment,
although the association with cancer diagnosis, factors
associated with opioid therapy and putative factors influencing
the pathogenesis of constipation have been studied
previously.2,5,38,39 Increasing age and female gender,4 over-
weight,40 lower Karnofsky performance status,39,41,42 hospi-
talization,38 longer time on opioids, higher opioid dose,5
certain opioid types,14,43 certain cancer diagnoses,4 presence
of metastases,38,39 and reduced mobility42,44 are all among
the proposed risk factors. However, most of these factors were
found not to be significantly associated with the inter-individual
variation in constipation in a clinically relevant sample of
cancer patients receiving opioids.2 Knowledge of factors
associated with the variation in constipation may help to
individualize treatment and avoid unnecessary patient suffer-
ing in the future. The present study aimed to identify possible
genetic and non-genetic factors associated with the inter-
individual variation in constipation among cancer patients
receiving opioids.
METHODS
Patients. The European Pharmacogenetic Opioid Study
included 2,294 patients receiving opioids for cancer pain,
from 17 centers in 11 countries.45 Included patients were 18
years or older, had a verified diagnosis of malignant disease,
agreed to give a blood sample and had received scheduled
opioid treatment corresponding to step III at the WHO
analgesic ladder for at least 3 days.46 Patients who lacked
a basic proficiency of the language spoken in the study center
were excluded. Because some chemotherapies cause
constipation and others cause diarrhea,2 patients receiving
chemotherapy were excluded (N=353). For the analyses of
genetic association we also excluded non-Caucasians
(N=47) and Greek patients (N=5) to minimize heterogene-
ity. Samples in which no genomic DNA was available (N= 20)
or where all genotyping failed (N= 2) and patients not
answering the question about constipation (N=299) were
also excluded. Finally, as all patients receiving step III opioids
should have laxatives prescribed according to guidelines, we
analyzed those receiving laxatives (N= 806) and those not
receiving laxatives (N= 762) separately, as we did not know
the reason for lack of laxative prescription.
The study was approved by ethical committees at each
study center or in each country before initialization and
performed according to the rules of the Helsinki-declaration.
Written informed consent was obtained fromall patients before
inclusion.
Patients reported constipation and their need to stay in bed
or a chair during the day by answering the European
Organization for Research and Treatment of Cancer Core
Quality of Life Questionnaire (EORTC-QLQ-C30).47 The
constipation intensity and extent of mobility during the past
week were assessed on a four-point verbal rating scale with
categories of “not at all, a little, quite a bit and very much”. The
exact questions were: “Have you been constipated?” for
constipation and “Do you need to stay in bed or a chair during
the day?” for mobility. Whole blood was drawn for pharmaco-
genetic analyses.
As prevalence and intensity of constipation might also be
influenced by a number of non-genetic factors,2,4,38–42 these
were also registered to be included as covariates in the
analyses of genetic association. Health-care providers (phy-
sician or nurse) registered age, gender, body mass index
(BMI), time since start of opioids (months), opioid dose (total
oral morphine equivalent daily dose in mg), cancer diagnosis,
presence of metastasis, type of laxatives used during the past
24 h, type of opioid, affiliation to department, and country. In
addition, the providers assessed Karnofsky performance
status,48 and cognitive function by the mini-mental state
examination (MMSE).49
SNP selection, genotyping and quality control. Within 16
candidate genes, 88 putative single-nucleotide polymor-
phisms (SNPs) were selected based on a combination of
associations identified in literature, available information in
databases,50–53 their frequency, functionality and their inter-
related distance (Supplementary Table 1 online). For SNP
selection the SNP browser version 3.5 (Applied Biosciences,
Foster City, CA, USA) was used to ensure that all selected
SNPs had an expected allele frequency of 10% or more in
Caucasians and that they were compatible with assay rules.
Isolation of genomic DNA from EDTA whole blood was
performed at HUNT Biobank, Levanger, Norway by using the
Gentra Puregene blood kit (QIAGEN Science, MA, USA). The
SNPlex Genotyping Platform, including universal SNPlex
System kits and reagents and SNP-specific ligation probes,
was used (Applied Biosciences). Genotyping was performed
according to the supplier’s dry DNA protocol. The GeneMap-
per Software v4.0 (Applied Biosciences) and manual reading
was used to analyze the SNPlex signals. Quality control and
data cleaning was performed. Samples with low signals not
separable from negative controls and samples in whicho90%
of SNPs were genotyped were removed prior to analysis and
treated as missing data. SNPs with a callrate o90% and
SNPs with inconsistent clustering on inspection were
excluded from analyses.
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Statistics. Collection and organization of data was per-
formed by The Pain and Palliation Research Group,
Norwegian University of Science and Technology. The
statistical software STATA version 11.0 was used for all
analyses (StataCorp. 2009 STATA Statistical Software:
Release 11. College Station, TX, USA: StataCorp LP).
Genotype frequencies, allele frequency and carriage were
determined and quality checked. SNPs in which no genotypes
were recorded, SNPs where genotypes were not in Hardy–
Weinberg equilibrium (Χ2-test, Po0.0005) and SNPs with an
observed minor allele frequency (MAF)o5% were rejected.
Univariate regressions (ordered logistic and linear) were
performed to investigate the possible associations between
non-genetic factors and intensity of constipation as reported in
EORTC question 16. The factors explored were age, BMI,
KPS, time on opioids, opioid dose, gender, type of laxative,
mobility (as reported by EORTC question 4), type of opioid,
department, metastases, and cancer diagnosis. Age, BMI,
KPS, and opioid dose were analyzed both as continuous and
as dichotomised variables (age ≤ 60 vs. 460, BMI o25 vs.
≥25, KPS ≤ 80 vs. 480, dose≤300mg vs. 4300mg).5 All
factors significantly (Po0.05) associated with constipation in
univariate analyses were considered for inclusion as covari-
ates in the stepwise multivariate analysis stratified by country.
The identified non-genetic covariates were included in
stratified multivariate regression analyses on the association
between constipation and SNPs within the candidate genes
related to the opioid- or constipation-signaling pathways
(HTR3E, HTR4, HTR2A, TPH1, ADRA2A, CHRM3, TACR1,
CCKAR, KIT, ARRB2, GHRL, ABCB1, COMT, OPRM1,
OPRK1, and OPRD1). These ordered logistic regression
analyses, with constipation as the dependent variable (scored
0 for “Not at all”, 1 for “A little”, 2 for “Quite a bit” and 3 for “Very
much”) generated β-slopes. Analyses were also repeated
without the inclusion of covariates as a sensitivity check.
Unstratified analyses, not including covariates, were used to
compare symptom intensity between those carrying the “risk”
allele and those not.
To mitigate the issue of multiple testing we used a 10% false
discovery rate reporting the Benjamini–Hochberg (BH) thresh-
olds, the constipation question of EORTC was pre-specified
as the primary outcome and the codominant genetic model
was prespecified for the primary analyses (dominant, reces-
sive and additive models were exploratory). P values o0.01
were interpreted as suggestive of effects that should be
evaluated in future studies.
RESULTS
Patients. The demographic and disease-related character-
istics of the 1,568 patients included in this study are shown in
Table 1. Patients receiving laxatives were similar to those not
receiving laxatives regarding age (mean 63 and 61 years),
gender (59 and 49% male), BMI (24 and 23 kg/m2), KPS (60
and 63), mean MMSE total score,27 time since diagnosis
(31 months), presence of metastases (86 and 80%), cancer
diagnoses represented, and type of opioids prescribed. There
were more out-patients among those not receiving laxatives
(29%), as compared with patients receiving laxatives (13%).
Table 1 Patient demographics
Laxatives
(N=806)
No laxatives
(N=762)
Mean s.d. Mean s.d.
Age (years) 63.1 11.9 60.6 12.1
Body mass index (kg/m2) 23.8 4.6 23.3 4.6
Karnofsky performance status
(range 0–100)
60.0 16.2 62.7 16.6
Mini mental state, total score
(range 0–30)
26.7 3.5 27.2 3.0
Time since diagnosis (months) 31.1 44.8 30.6 44.2
N % N %
Gender
Female 333 41.3 390 51.2
Male 473 58.7 372 48.8
Department
Palliative care unit/hospice 272 33.7 226 29.7
General oncology ward 424 52.6 278 36.5
Surgical ward 7 0.9 35 4.6
Out-patients 103 12.8 223 29.3
Status of opioid treatment
Opioid recently initiated/titration 158 19.6 140 18.4
Stable dosing 642 79.7 616 80.8
Metastases
None 114 14.1 156 20.5
One or more 692 85.9 606 79.5
Cancer diagnosis
Breast 88 10.9 81 10.6
Female reproductive organs 48 6.0 79 10.4
Gastrointestinal 140 17.4 192 25.2
Hematological 38 4.7 39 5.1
Head and neck 34 4.2 62 8.1
Lung 173 21.5 113 14.8
Prostate 131 16.3 60 7.9
Urological 60 7.4 53 7.0
Other or unknown 128 15.9 114 15.0
Type of opioid
Morphine 366 45.4 254 33.3
Oxycodone 189 23.4 144 18.9
Fentanyl 174 21.6 277 36.4
Other 77 9.6 87 11.4
Country
Denmark 10 1.2 18 2.4
Finland 8 1.0 17 2.2
Germany 111 13.8 128 16.8
Iceland 65 8.1 50 6.6
Italy 116 14.4 191 25.1
Lithuania 0 0 41 5.4
Norway 271 33.6 130 17.1
Sweden 29 3.6 78 10.2
Switzerland 64 7.9 20 2.6
United Kingdom 132 16.4 89 11.7
Laxative treatment
Bulk 376 46.7
Stimulant 175 21.7
Combination and/or other 253 31.4
EORTC 16 Constipation
Not at all 160 19.9 327 42.9
A little 180 22.3 194 25.5
Quite a bit 233 28.9 153 20.1
Very much 233 28.9 88 11.5
EORTC 16, EuropeanOrganization for Research and Treatment of Cancer Core
Quality of Life Question number 16.
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Almost 80% were on stable dosing of opioids in both groups.
“Quite a bit” or “very much” constipation was reported by 58%
of patients receiving laxatives as compared with 32% among
those not receiving laxatives.
Association with non-genetic factors. In the univariate
analyses, the results of ordered logistic and linear regres-
sions were consistent. Five of the non-genetic factors were
considered as significantly associated with the intensity of
constipation (Table 2). These were type of laxative, mobility
as measured by EORTC question 4 and whether the patient
was an outpatient or admitted to a hospital among patients
receiving laxatives (all Po0.001). Karnofsky performance
status (P= 0.002) and presence of metastases (P=0.006)
were associated with intensity of constipation among patients
not receiving laxatives. In addition, the covariate “total daily
opioid dose (mg)” had a P value of 0.024 in univariate
analyses among patients treated with laxatives (Table 2). But
as this covariate had coefficients that were not very
consistent and reliable, was not a covariate among those
not receiving laxatives and was not strongly prognostic when
included in multivariate analyses (those underlying Table 3), it
was dropped for further analyses (see also Supplementary
Table 2). The five significant factors were included as
covariates in the multivariate regressions of genetic factors.
The distributions of the responses for the EORTC constipa-
tion score in relation to the identified non-genetic factors are
reported in Table 3.
Genotype distributions. The success rates of genotyping
and frequencies of genotypes and alleles are shown in
Supplementary Table 1 online. Out of the 88 candidate
SNPs, 13 were excluded from analyses because of deviation
from the Hardy–Weinberg equilibrium or a low observed
MAF (o 5%). These were rs34826744 in HTR4, rs13306143
and rs3750625 in ADRA2A, rs2237037 in KIT, rs16954146,
and rs7208257 in ARRB2, rs34911341 in GHRL, rs1202181
in ABCB1, rs7815824 in OPRK1, rs1042114, rs204048,
rs2234918, and rs204076 in OPRD1. The remaining 75
SNPs were further analyzed.
Table 2 Non-genetic factors associated with constipation in univariate analyses
Receiving laxatives (N=806) No laxatives (N= 762)
β 95% CI P β 95% CI P
Age (years)
≤ 60 (0) 0.003 − 0.003 to 0.009 0.339 0.004 − 0.002 to 0.010 0.187
460 (1) 0.084 − 0.070 to 0.239 0.284 0.115 − 0.033 to 0.264 0.128
BMI (kg/m2)
o25 (0) −0.007 − 0.024 to 0.010 0.402 −0.000 − 0.016 to 0.016 0.997
≥25 (1) 0.022 − 0.141 to 0.185 0.794 −0.066 − 0.228 to 0.096 0.424
KPS (range 0–100)
≤ 80 (0) −0.001 −0.005 to 0.004 0.776 −0.003 −0.008 to 0.001 0.171
480 (1) −0.381 −0.763 to −0.000 0.050 −0.457 −0.750 to −0.164 0.002
Time since start opioids −0.048 −0.106 to 0.010 0.108 0.048 − 0.009 to 0.104 0.101
Total daily dose (g) 0.141 −0.264 to −0.019 0.024 0.148 − 0.033 to 0.328 0.109
Gender
Male (0), female (1) 0.104 − 0.050 to 0.258 0.185 −0.079 − 0.228 to 0.070 0.298
Type of opoid
Morphine (0= no, 1= yes), oxycodone
(0=no, 1= yes), fentanyl (0=no, 1= yes),
other (0=no, 1= yes)
−0.042 − 0.277 to 0.193 0.725 −0.138 − 0.315 to 0.039 0.127
Metastases
None (0), ≥ one (1) 0.167 − 0.049 to 0.382 0.129 0.259 0.076 to 0.441 0.006
Cancer diagnosis
Other (0), gastrointestinal or female reproductive organs (1) −0.116 − 0.295 to 0.063 0.203 −0.096 − 0.252 to 0.059 0.225
Laxative treatment
Bulk (0=no, 1= yes), stimulant (0=no, 1= yes),
combination and/or other (0=no, 1= yes)
0.212 0.126 to 0.297 o0.001
Reduced mobility
Not at all, a little, quite a bit, very much 0.178 0.100 to 0.256 o0.001 −0.001 − 0.077 to 0.075 0.979
Department
Outpatient (0), hospitalized (1) 0.533 0.309 to 0.757 o0.001 −0.079 − 0.242 to 0.085 0.345
BMI, body mass index; CI, confidence interval; KPS, Karnofsky performance status.
Results of linear regression. The results of ordered logistic regression (not shown) were closely similar. The dependent variable, constipation, was scored as 0 for “Not
at all”, 1 for “A little”, 2 for “Quite a bit”, and 3 for “Verymuch”. Note: analyseswere stratified by country. Age, BMI, and KPSwere investigated both as continuous and as
dichotomous variables.
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Association with genetic factors. The non-genetic risk
factors identified as statistically significant in Tables 2 and 3
were included in the multivariate analysis underlying Tables 4
and 5, where significant non-genetic risk factors were
combined with genetic risk factors in a multivariable model.
As shown in Table 4, the genetic factors associated with con-
stipation among patients receiving laxatives were rs1800532
within TPH1 in a codominant model, rs1799971 within
OPRM1 in additive and dominant models, as well as
rs4437575 within ABCB1 and rs10802789 within CHRM3 in
a dominant model (Po0.01). None of these associations
passed the BH criterion for a 10% false discovery rate. As
shown in Table 5, the genetic factor associated with constipa-
tion among patients not receiving laxatives was rs2020917
within COMT in a codominant model. This association passed
the BH criterion for a 10% false discovery rate.
More patients reported “quite a bit” or “very much” consti-
pation among those not carrying the C-allele of rs1800532 in
TPH1 (64%) and those not carrying the G-allele of rs1799971
in OPRM1 (63%). More patients reported “quite a bit” or “very
much” constipation among those carrying the G-allele of
rs4437575 in ABCB1 (61%), the T-allele of rs10802789 in
CHRM3 (60%) or the T-allele of rs2020917 in COMT (36%).
DISCUSSION
The inter-individual differences in constipation among patients
receiving opioids are associated with the type of laxative
administered, level of mobility, place of care, Karnofsky
performance status, presence of metastases and five
polymorphisms within TPH1, OPRM1, ABCB1, CHRM3, and
COMT (Po0.01).
The characteristics of included patients (Table 1) were as
expected for cancer patients.54 We found that 58% of patients
receiving laxatives and 32% of patients not receiving laxatives
reported “quite a bit” or “very much” constipation. These
numbers indicate the large inter-individual variation in
constipation among cancer patients receiving opioids, with
some patients being constipated despite optimized treatment
with laxatives and some not experiencing constipation despite
high doses of opioids.55
In agreement with other studies we observed that type
of laxative,56,57 hospitalization,38 reduced mobility,42,44
Karnofsky performance status,41,42 and presence of
metastases38 influence whether a cancer patient report to
experience constipation when receiving opioids.
The results of our study indicate that polymorphisms within
TPH1 may contribute to the inter-individual variations in
constipation. Tryptophan hydroxylase (TPH) is the rate-
limiting enzyme in enterochromaffin (EC) cell 5-HT biosynth-
esis. Following luminal chemical and mechanical signals, the
EC-cells release 5-HT, which stimulates 5-HT3 and 5-HT4
receptors on primary afferent neurons, inducing secretomotor
and peristaltic reflexes of the intestines.58 A common TPH1
proximal promoter variant (rs7130929, −347C4A) has been
associated with the diarrheal subtype of irritable bowel
syndrome (IBS).59 Because of the distance to polymorphism
rs1800532 (also known as 218A4C, located in intron 7) it is
difficult to compare the findings of this study with ours. A study
among female, Caucasian IBS patients found no association
Table 3 Non-genetic factors associated with constipation in multivariate analyses
Receiving laxatives (N = 806) No laxatives (N = 762)
Not at all A little Quite
a bit
Very
much
Total Not at all A little Quite
a bit
Very
much
Total
N % N % N % N % N β
95% CI
P
N % N % N % N % N β
95% CI
P
KPS (range 0–100) 0.536
≤ 80 (0) 299 42 176 25 147 21 88 12 710 0.318–0.906
480 (1) 28 54 18 35 6 12 0 0 52 0.020
Metastases 1.599
None (0) 86 55 33 21 22 14 15 10 156 1.139–2.243
≥ one (1) 241 40 161 27 131 22 73 12 606 0.007
Laxative treatment
Bulk 88 23 98 26 96 26 94 25 376 0.426
Stimulant 34 19 42 24 66 38 33 19 175 0.273–0.579
Combination/other 38 15 39 15 71 28 105 42 253 o0.001
Reduced mobility
Not at all 27 36 23 30 15 20 11 14 76 0.272
A little 42 25 34 20 39 23 52 31 167 0.134–0.409
Quite a bit 43 15 69 25 95 34 73 26 280 o0.001
Very much 48 17 53 19 82 29 97 35 280
Department 0.906
Outpatient (0) 34 33 29 28 25 24 15 15 103 0.524–1.287
Hospitalized (1) 126 18 151 21 208 30 218 31 703 o0.001
BMI, body mass index; CI, confidence interval; KPS, Karnofsky performance status.
Results of linear regression. The results of ordered logistic regression (not shown) were closely similar. The dependent variable, constipation, was scored as 0 for “Not
at all”, 1 for “A little”, 2 for “Quite a bit”, and 3 for “Very much”. Because of a few missing values, some counts does not add up to 100%.
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between the diagnosis and five SNPs, including the
rs1800532.60
Our findings suggest that polymorphisms within OPRM1
may be associated with intensity of constipation in cancer
patients receiving opioids. The non-synonymous SNP
rs1799971 in exon 1 (118A4G, Asp40Asn) has repeatedly
demonstrated a functional effect.61 The effect on analgesia
and pain sensitivity is extensively studied, with carriers of the
minor 118G allele having a decreased analgesic response to
morphine andM6G.27 Interestingly, only a few of the 118A4G-
studies have addressed the association with intensity of
constipation and no effect was found.27 However, in these
studies, constipation was only measured as a secondary
outcome. In the preclinical setting carriage of the 118G allele is
associated with lower levels of mu-opioid receptor mRNA and
protein, higher potency and mu-opioid receptor affinity for
beta-endorphin and lower potency for exogenous opioids.61
Clinically, carriage of the 118G allele is associated with higher
sensitivity to pain, a need for higher opioid doses to reach
analgesic effect and an unchanged or lower risk of opioid-
related side effects.61 In agreement with this, we found that
more patients reported “quite a bit” or “very much” constipation
among those not carrying the G-allele of 118A4G.
Polymorphisms within the ABCB1 gene (also known as
MDR1) may influence intensity of constipation as the product
of this gene, P-glycoprotein, is a transporter of many drugs,
including opioids. As for OPRM1, there are many studies
addressing the influence of ABCB1-polymorphisms on pain
sensitivity and opioid analgesia, but only a few on associations
with opioid effects other than analgesia.27 In a study
prospectively recruiting 228 cancer patients receiving mor-
phine, genetic variation in the ABCB1 gene was associated
with drowsiness, confusion, and hallucination.62 No such
association was observed with constipation. The polymorph-
ism rs4437575 investigated in our study is located within
the same haploblock as the more known 3435C4T in
exon 26 (rs1045642). In the present study more patients
reported “quite a bit” or “very much” constipation among those
carrying the minor G-allele of rs4437575. This finding is as
expected, considering the strong linkage between rs4437575
and rs1045642, where carriage of the minor T-allele in the
latter SNP is associated with more opioid-related side
effects.63
The results also indicated possible associations between
SNPs inCHRM3 and constipation in cancer patients receiving
opioids. Cholinergic muscarine receptor 3 (CHRM3) is found
Table 4 Genetic factors possibly associated with constipation among patients receiving laxatives (N= 806)
Gene Genotype Absolute number of patients Multivariate analysis P value allelesa
SNP Allele Not at all A little Quite a bit Very much Total OR 95% CI Pb Model
N % N % N % N %
TPH1
rs1800532 AA 26 20 21 16 36 27 48 37 131
AC 85 22 93 25 101 27 99 26 378 1.457 1.126–1.885 0.004 Codominant
CC 42 16 59 22 87 33 79 30 267
C 127 20 152 24 188 29 178 28 645 0.094
Not C 26 20 21 16 36 27 48 37 131
OPRM1
rs1799971 AA 84 17 97 20 150 31 152 31 483 0.664 0.500–0.882 0.005 Additive
AG 35 22 44 28 40 26 37 24 156 1.523 1.110–2.090 0.009 Dominant
GG 2 25 3 38 2 25 1 13 8
G 37 23 47 29 42 26 38 23 164 0.005
Not G 84 17 97 20 150 31 152 31 483
ABCB1
rs4437575 AA 60 24 60 24 64 26 65 26 249 0.687 0.520–0.908 0.008 Dominant
AG 64 17 92 24 117 31 107 28 380
GG 31 20 23 15 46 30 53 35 153
G 95 18 115 22 163 31 160 30 533 0.028
Not G 60 24 60 24 64 26 65 26 249
CHRM3
rs10802789 CC 46 22 52 25 61 30 46 22 205 0.667 0.497–0.896 0.007 Dominant
CT 53 16 75 23 102 31 101 31 331
TT 25 18 31 23 38 28 42 31 136
T 78 17 106 23 140 30 143 31 467 0.013
Not T 46 22 52 25 61 30 46 22 205
COMT
rs2020917 CC 55 17 66 20 100 31 103 32 324
CT 59 22 60 23 77 29 69 26 265 1.202 0.903–1.601 0.207 Codominant
TT 9 15 19 32 14 24 17 29 59
T 68 21 79 24 91 28 86 27 324 0.042
Not T 55 17 66 20 100 31 103 32 324
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
The odds ratios are from ordered logistic regression with constipation as the dependent variable, scored as 0 for “Not at all”, 1 for “A little”, 2 for “Quite a bit”, and 3 for
“Very much”. Because of a few missing values, some counts does not add up to 100%.
aP value of unstratified analyses without the inclusion of covariates.
bP values of ordered logistic regression in the analyses allowing for covariates and stratified by country.
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in the intestinal wall,64 and CHRM3 antagonists have been
shown to inhibit intestinal motility.65 Genetic variation within
the CHRM3 gene (rs3738435) has been tested for an
association with IBS and specifically for an association with
the constipation subtype, but no such associations were
found.66 The SNP rs10802789, also known as c.-249-8806C
4 T, has been associated with intensity of nausea/vomiting in
a previous study.67 To our knowledge, the exact functional
consequence of this polymorphism is still unknown.
The association between constipation and rs2020917 in
COMT among cancer patients not receiving laxatives passed
the BH criterion. More patients reported “quite a bit” or “very
much” constipation among those carrying the T-allele of
rs2020917 in COMT (36%). The variant rs2020917 is located
in the 5′ regulatory promoter of the membrane-bound-COMT
isoform and it has been shown to alter nuclear protein binding
patterns, thereby upregulating transcription and possibly
increasing COMT enzyme activity.68 On the contrary,
it has also been demonstrated that the haploblock containing
the T-allele of rs2020917 and the C-allele of the nearby
rs737865 is associated with reduced COMT-transcription.69
Decreased enzyme-activity, as coded by the Met-allele of
the Val158Met (rs4680) variant has been associated with
enhanced activation of dopaminergic neurotransmission and
lower opioid-dose requirement.70 In animal models, chronic
activation of dopaminergic neurotransmission reduces the
neuronal content of enkephalin peptides,71 leading to an
upregulation of mu-opioid receptors.72 Taken together, our
finding agrees with the existing literature on lower opioid-dose
requirements and possibly increased adverse effects asso-
ciated with reduced COMT-transcription and enzyme-activity.
There are several challenges of candidate gene association
research, and we recognize some in the present study. First,
there is a lack of a stringent definition of constipation among
cancer patients receiving opioids. Hence, comparison of
results between studies is difficult and there is no agreement
on definition of the phenotype.73 This study, including more
patients than other studies addressing genetic variability
related to opioid effects, utilized the EORTC QLQ-C30, a
well-validated assessment tool, formally translated into many
languages to define the phenotype. Other studies may also
include objective measures such as number of stools and
similar outcomes. Second, symptom intensity was registered
for the past week, whereas administration of laxatives was
registered for the past 24 h. However, we believe use of
laxativeswas related to symptom intensity as assessments for
the past 24 h and the past week are closely related in cancer
patients.74 Third, this study did not take into consideration
gene–gene interactions, gene–environment interactions or
epigenetics. However, genetic features in favor of the present
study are that genes and polymorphisms were chosen based
on known biology and pathophysiology, population stratifica-
tion was avoided by only including Caucasians, measures
have been undertaken to control for false positive findings,
more than a few candidate SNPs were included in the
analyses, and potential clinical confounding factors were
identified and included in the analyses. Finally, as no
replication sample was included, the findings should be
repeated in an independent study before the associations
could be regarded as conclusive.
CONCLUSION
This study suggests that type of laxative, mobility, hospitaliza-
tion, Karnofsky performance status, presence of metastases
and five SNPs within TPH1, OPRM1, ABCB1, CHRM3, and
COMT are associated with the variability in constipation
among cancer patients treated with opioids (Po0.01). Only
rs2020917 in COMT passed the BH criterion for a 10% false
discovery rate. Genetic associations can be helpful to
elucidate the relevant biological mechanisms for constipation
in patients treated with opioids. These biological mech-
anisms can therefore be identified as targets for developing
new and improved therapy for constipation in patients
receiving opioids. Before introduction of genetic testing in
routine patient care, large prospective studies are needed to
determine whether genetic testing of polymorphisms helps to
predict the risk and treatment of constipation among cancer
patients receiving opioids, and whether this is a cost-effective
approach.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ There is inter-individual variation in both analgesic
response and constipation among patients receiving
opioids.
✓ There is a surprising lack of evidence to guide the choice of
laxative treatment for the individual patient.
WHAT IS NEW HERE
✓ Type of laxative, mobility, hospitalization, Karnofsky
performance status, presence of metastases and five SNPs
within TPH1, OPRM1, ABCB1, CHRM3, and COMT may
contribute to the variability in constipation among cancer
patients receiving opioids.
✓ Our findings reveal relevant biological mechanisms for
constipation that might contribute to developing new and
improved therapy for constipation in patients receiving
opioids.
Factors of Constipation in Cancer Patients on Opioids
Laugsand et al.
8
Clinical and Translational Gastroenterology
1. Sykes NP. A volunteer model for the comparison of laxatives in opioid-related constipation.
J Pain Symptom Manage 1996; 11: 363–369.
2. Droney J, Ross J, Gretton S et al. Constipation in cancer patients on morphine. Support
Care Cancer 2008; 16: 453–459.
3. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new
therapies. Drugs 2003; 63: 649–671.
4. Mancini IL, Hanson J, Neumann CM et al. Opioid type and other clinical predictors of laxative
dose in advanced cancer patients: a retrospective study. J Palliat Med 2000; 3: 49–56.
5. Clark K, Smith JM, Currow DC. The prevalence of bowel problems reported in a palliative
care population. J Pain Symptom Manage 2012; 43: 993–1000.
6. Laugsand EA, Jakobsen G, Kaasa S et al. Inadequate symptom control in advanced cancer
patients across Europe. Support Care Cancer 2011; 19: 2005–2014.
7. Miles CL, Fellowes D, Goodman ML et al. Laxatives for the management of constipation in
palliative care patients. Cochrane Database Syst Rev 2006;CD003448.
8. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;
6: 356–364.
9. Sanger GJ. 5-hydroxytryptamine and the gastrointestinal tract: where next? Trends
Pharmacol Sci 2008; 29: 465–471.
10. Niesler B, Frank B, Kapeller J et al. Cloning, physical mapping and expression analysis of the
human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310:
101–111.
11. Wouters MM, Farrugia G, Schemann M. 5-HT receptors on interstitial cells of Cajal, smooth
muscle and enteric nerves. Neurogastroenterol Motil 2007; 19: 5–12.
12. Kapeller J, Houghton LA, Moennikes H et al. First evidence for an association of a functional
variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea
predominant irritable bowel syndrome. Hum Mol Genet 2008; 17: 2967–2977.
13. Moulin DE, Rykx A, Kerstens R et al. Randomized, double-blind, placebo-controlled trial to
evaluate efficacy and safety of prucalopride (Resolor (R)) in patients with opioid-induced.
Gastroenterology 2008; 134: A92–A92.
14. DeLuca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Therapeut
1996; 69: 103–115.
15. Dhasmana KM, Banerjee AK, Faithfull NS et al. Role of 5-hydroxytryptamine receptors to
narcotic-induced reduction in gastrointestinal transit in rats. Zhongguo Yao Li Xue Bao 1986;
7: 499–503.
16. Costedio MM, Coates MD, Brooks EM et al.Mucosal serotonin signaling is altered in chronic
constipation but not in opiate-induced constipation. Am J Gastroenterol 2010; 105:
1173–1180.
17. Hikasa Y, Akiba T, Iino Y et al. Central alpha-adrenoceptor subtypes involved in the emetic
pathway in cats. Eur J Pharmacol 1992; 229: 241–251.
18. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroent
Motil 2004; 16 (Suppl 2): 17–28.
19. Garzon J, Hollt V, Herz A. Cholecystokinin octapeptide activates an opioid mechanism
in the guinea-pig ileum: a possible role for substance P. Eur J Pharmacol 1987; 136:
361–370.
20. Garcia-Barcelo M, King SK, Miao XP et al. Application of HapMap data to the evaluation of 8
candidate genes for pediatric slow transit constipation. J Pediatr Surg 2007; 42: 666–671.
21. Wiesenfeld-Hallin Z, de Arauja Lucas G, Alster P et al. Cholecystokinin/opioid interactions.
Brain Res 1999; 848: 78–89.
22. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents.
Neurogastroenterol Motil 2005; 17: 643–653.
23. Cremonini F, Camilleri M, McKinzie S et al. Effect of CCK-1 antagonist, dexloxiglumide, in
female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic
study. Am J Gastroenterol 2005; 100: 652–663.
24. Poitras P, Polvino WJ, Rocheleau B. Gastrokinetic effect of ghrelin analog RC-1139 in the
rat: effect on post-operative and on morphine induced ileus. Peptides 2005; 26: 1598–1601.
25. Tong WD, Liu BH, Zhang LY et al. Analysis of the c-kit gene in patients with slow transit
constipation. Gut 2006; 55: 1207–1208.
26. Banach T, Zurowski D, Gil K et al. Peripheral mechanisms of intestinal dysmotility in the
morphine tolerant and dependent rats. J Physiol Pharmacol 2006; 57: 73–82.
27. Skorpen F, Laugsand EA, Klepstad P et al. Variable response to opioid treatment: any
genetic predictors within sight? Palliat Med 2008; 22: 310–327.
28. Campa D, Gioia A, Tomei A et al. Association of ABCB1/MDR1 and OPRM1 gene
polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559–566.
29. Coulbault L, Beaussier M, Verstuyft C et al. Environmental and genetic factors associated with
morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79: 316–324.
30. Fujita K-I, Ando Y, Yamamoto W et al. Association of UGT2B7 and ABCB1 genotypes with
morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer
Chemoth Pharm 2010; 65: 251–258.
31. Oostenbrug LE, Dijkstra G, Nolte IM et al. Absence of association between the multidrug
resistance (MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol 2006; 41:
1174–1182.
32. Rakvag TT, Klepstad P, Baar C et al. The Val158Met polymorphism of the human catechol-
O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain
patients. Pain 2005; 116: 73–78.
33. Obayashi K, Olsson M, Anan I et al. Impact of serotonin transporter and catechol-O-methyl
transferase genes polymorphism on gastrointestinal dysfunction in Swedish and Japanese
familial amyloidotic polyneuropathy patients. Clin Chim Acta 2008; 398: 10–14.
34. Bohn LM, Raehal KM. Opioid receptor signaling: relevance for gastrointestinal therapy. Curr
Opin Pharmacol 2006; 6: 559–563.
35. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J
2005; 7: E587–E591.
36. Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice.
J Pharmacol Exp Ther 2005; 314: 1195–1201.
37. Pineyro G, Archer-Lahlou E. Ligand-specific receptor states: implications for opiate receptor
signalling and regulation. Cell Signal 2007; 19: 8–19.
38. Johnsen AT, Petersen MA, Pedersen L et al. Symptoms and problems in a nationally
representative sample of advanced cancer patients. Palliative Med 2009; 23: 491–501.
39. Jordhoy MS, Fayers P, Loge JH et al. Quality of life in advanced cancer patients: the impact
of sociodemographic and medical characteristics. Brit J Cancer 2001; 85: 1478–1485.
40. Pourhoseingholi MA, Kaboli SA, Pourhoseingholi A et al. Obesity and functional constipation;
a community-based study in Iran. J Gastrointestin Liver Dis 2009; 18: 151–155.
41. Fallon MT, Hanks GW. Morphine, constipation and performance status in advanced cancer
patients. Palliat Med 1999; 13: 159–160.
42. Bennett M, Cresswell H. Factors influencing constipation in advanced cancer patients: a
prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 2003;
17: 418–422.
43. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in
cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative
Trial Group. J Pain Symptom Manag 1997; 13: 254–261.
44. Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer
patients. Support Care Cancer 2004; 12: 613–618.
45. Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for
cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011;
152: 1139–1145.
46. WHO Cancer Pain Relief and Palliative Care. Geneva, Switzerland: WHO. 1990.
47. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and
Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical
trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.
48. Karnofsky D, Abelmann W, Craver L, Burchenal JH. The use of nitrogen mustard in the
palliative treatment of cancer. Cancer 1948; 1: 634–656.
49. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading
the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
50. SNPper. Available from http://snpper.chip.org/bio/snpper-enter.
51. dbSNP. Available from http://www.ncbi.nlm.nih.gov/projects/SNP.
52. Ensembl. Available from http://www.ensembl.org.
53. HapMap Genome Browser. Available from http://www.hapmap.org.
54. Teunissen SCCM, Wesker W, Kruitwagen C et al. Symptom prevalence in patients with
incurable cancer: A systematic review. J Pain Symptom Manag 2007; 34: 94–104.
55. Davis MP. Cancer constipation: are opioids really the culprit? Support Care Cancer 2008; 16:
427–429.
56. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic
constipation: systematic review. Am J Gastroenterol 2005; 100: 936–971.
57. Sykes NP. A clinical comparison of laxative in a hospice. Palliat Med 1991; 5: 363.
58. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug
development for functional GI disorders. Gastroenterology 2007; 132: 397–414.
59. Grasberger H, Chang L, Shih W et al. Identification of a functional TPH1 polymorphism
associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol 2013;
108: 1766–1774.
60. Jun S, Kohen R, Cain KC et al. Associations of tryptophan hydroxylase gene
polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2011; 23:
233–239 e116.
61. Mura E, Govoni S, Racchi M et al. Consequences of the 118A4G polymorphism in the
OPRM1 gene: translation from bench to bedside? J Pain Res 2013; 6: 331–353.
62. Ross JR, Riley J, Taegetmeyer AB et al. Genetic variation and response to morphine in
cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorph-
isms are associated with central side effects. Cancer 2008; 112: 1390–1403.
63. Rhodin A, Gronbladh A, Ginya H et al. Combined analysis of circulating beta-endorphin with
gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid
sensitivity and opioid-related side effects. Mol Brain 2013; 6: 8.
64. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function.
Pharmacol Rev 1996; 48: 531–565.
65. Thollander MSL, S, Chiba T, Sarr MG, Philips SF. Cholinergic control of colonic tone.
Gastroenterology 1998; 114: A847.
66. Onodera S, Chiba T, Sugai T et al. A genetic association between ss3-aderenoceptor and
cholinergic receptor muscarinic 3 polymorphisms in irritable bowel syndrome. Hepatogas-
troenterology 2011; 58: 1474–1478.
67. Laugsand EA, Fladvad T, Skorpen F et al. Clinical and genetic factors associated with
nausea and vomiting in cancer patients receiving opioids. Eur J Cancer 2011; 47:
1682–1691.
68. Hatzimanolis A, Vitoratou S, Mandelli L et al. Potential role of membrane-bound COMT gene
polymorphisms in female depression vulnerability. J Affect Disord 2013; 148: 316–322.
69. Bortsov AV, Diatchenko L, McLean SA. Complex multilocus effects of catechol-O-
methyltransferase haplotypes predict pain and pain interference 6 weeks after motor vehicle
collision. Neuromolecular Med 2014; 16: 83–93.
Factors of Constipation in Cancer Patients on Opioids
Laugsand et al.
9
Clinical and Translational Gastroenterology
70. Rakvag TT, Ross JR, Sato H et al. Genetic variation in the catechol-O-methyltransferase
(COMT) gene and morphine requirements in cancer patients with pain.Mol Pain 2008; 4: 64.
71. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output
pathways and behavior. Exp Brain Res 1998; 123: 60–76.
72. Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist
quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and
proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
Neuroscience 1993; 54: 669–680.
73. Gaertner J, Siemens W, Camilleri M et al. Definitions and outcome measures of clinical trials
regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2015; 49:
9–16.
74. Shi QL, Trask PC, Wang XS et al. Does recall period have an effect on cancer patients'
ratings of the severity of multiple symptoms? J Pain Symptom Manag 2010; 40: 191–199.
Clinical and Translational Gastroenterology is an open-
access journal published by Nature Publishing Group.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in the credit line;
if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies this paper on the Clinical and Translational Gastroenterology website (http://www.nature.com/ctg)
Factors of Constipation in Cancer Patients on Opioids
Laugsand et al.
10
Clinical and Translational Gastroenterology
